Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

Summary

The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.

Timeline

Start

2007-07-17

Primary completion

2008-07-23

Completion

2008-07-23

Outcome

Mixed primary results

registry analysis (superiority test); Placebo vs GSK232802 75 mg; p = 0.041; Adjusted Mean Difference 1.21 (95% CI 0.05 to 2.37) NCT00604825 ↗

registry analysis (superiority test); Placebo vs GSK232802 75 mg; p = 0.008; Adjusted Mean Difference 0.31 (95% CI 0.08 to 0.54) NCT00604825 ↗

registry analysis (superiority test); Placebo vs GSK232802 25 mg; p = 0.215; Adjusted Mean Difference 0.75 (95% CI -0.44 to 1.93) NCT00604825 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	GSK232802	Small molecule	—	Oral
Subject	conjugated estrogens	Other / unclassified	—	—

Indications

No indication recorded.